GW Pharmaceuticals PLC- (GWPH) Receives Daily News Impact Score of 0.27
Press coverage about GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been trending positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.6743281688377 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session – Nasdaq (nasdaq.com)
- Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Post Quarterly Sales of $2.14 Million (americanbankingnews.com)
- Cannabis Stock Report: GW Pharma Re-Acquires Sativex – PotNetwork (blog) (potnetwork.com)
- Goldman Sachs Sees 40% Upside In GW Pharmaceuticals – Benzinga (benzinga.com)
- GW Pharmaceuticals PLC- (GWPH) Lifted to “Buy” at Goldman Sachs Group (americanbankingnews.com)
GWPH has been the subject of a number of research reports. Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective for the company in a report on Thursday. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Monday, December 4th. Bank of America cut their target price on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research note on Tuesday, November 14th. ValuEngine upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Cowen reiterated an “outperform” rating and issued a $165.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $148.78.
GW Pharmaceuticals PLC- (GWPH) traded down $0.61 during mid-day trading on Friday, reaching $130.21. The company’s stock had a trading volume of 527,778 shares, compared to its average volume of 429,295. GW Pharmaceuticals PLC- has a 12 month low of $92.65 and a 12 month high of $136.95. The company has a current ratio of 7.59, a quick ratio of 7.47 and a debt-to-equity ratio of 0.02.
COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Receives Daily News Impact Score of 0.27” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/12/16/gw-pharmaceuticals-plc-gwph-receives-daily-news-impact-score-of-0-27.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.